E2F8 and hepatocellular carcinoma: Also, E2F8 high level contributed to 1-year recurrence, 3-year recurrence and 5-year recurrence in HCC patients (HR = 2.33, P = 9.7E-05; HR = 1.74, P = 0.0017 and HR = 1.7, P = 0.0017, respectively, Figure 3F–H).